Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.

Ohr M, Kaiser PK.

Expert Opin Pharmacother. 2012 Mar;13(4):585-91. doi: 10.1517/14656566.2012.658368. Epub 2012 Feb 3. Review.

PMID:
22300011
2.

Aflibercept in wet age-related macular degeneration: a perspective review.

Ohr M, Kaiser PK.

Ther Adv Chronic Dis. 2012 Jul;3(4):153-61. doi: 10.1177/2040622312446007.

3.

Aflibercept for age-related macular degeneration: a game-changer or quiet addition?

Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW.

Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020. Review.

PMID:
22813448
4.

Intravitreal aflibercept for neovascular age-related macular degeneration.

Xu D, Kaiser PK.

Immunotherapy. 2013 Feb;5(2):121-30. doi: 10.2217/imt.12.158.

PMID:
23413903
5.

Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.

Yazdi MH, Faramarzi MA, Nikfar S, Falavarjani KG, Abdollahi M.

Expert Opin Biol Ther. 2015;15(9):1349-58. doi: 10.1517/14712598.2015.1057565. Epub 2015 Jun 16. Review.

PMID:
26076760
6.

Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).

Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF.

Retina. 2012 Mar;32(3):434-57. doi: 10.1097/IAE.0B013E31822C290F.

PMID:
22374154
7.
8.

Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration.

Fauser S, Schwabecker V, Muether PS.

Am J Ophthalmol. 2014 Sep;158(3):532-6. doi: 10.1016/j.ajo.2014.05.025. Epub 2014 May 28.

PMID:
24879948
9.

Current therapeutic approaches in neovascular age-related macular degeneration.

Nguyen DH, Luo J, Zhang K, Zhang M.

Discov Med. 2013 Jun;15(85):343-8. Review.

10.

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept.

Stewart MW.

Clin Ophthalmol. 2012;6:1175-86. doi: 10.2147/OPTH.S33372. Epub 2012 Jul 26.

11.

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.

Stewart MW.

Expert Rev Clin Pharmacol. 2013 Mar;6(2):103-13. doi: 10.1586/ecp.12.81. Review.

PMID:
23473589
12.

Aflibercept for the treatment of neovascular age-related macular degeneration.

Verner-Cole EA, Davis SJ, Lauer AK.

Drugs Today (Barc). 2012 May;48(5):317-29. doi: 10.1358/dot.2012.48.5.1805931. Review.

PMID:
22645720
13.

VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.

Dixon JA, Oliver SC, Olson JL, Mandava N.

Expert Opin Investig Drugs. 2009 Oct;18(10):1573-80. doi: 10.1517/13543780903201684. Review.

PMID:
19694600
14.

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

Scott AW, Bressler SB.

Curr Opin Ophthalmol. 2013 May;24(3):190-6. doi: 10.1097/ICU.0b013e32835fefee. Review.

PMID:
23492430
15.

Anti-VEGF agents for age-related macular degeneration.

Ozkiris A.

Expert Opin Ther Pat. 2010 Jan;20(1):103-18. doi: 10.1517/13543770902762885. Review.

PMID:
20021287
16.

Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.

Frampton JE.

Drugs Aging. 2012 Oct;29(10):839-46. doi: 10.1007/s40266-012-0015-2. Review.

PMID:
23038609
17.
18.

Ranibizumab for age-related macular degeneration.

Dhoot DS, Kaiser PK.

Expert Opin Biol Ther. 2012 Mar;12(3):371-81. doi: 10.1517/14712598.2012.660523. Epub 2012 Feb 6. Review.

PMID:
22309606
19.

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.

PMID:
19815292
20.

[Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].

Michels S, Rosenfeld PJ.

Klin Monbl Augenheilkd. 2005 Jun;222(6):480-4. Review. German.

PMID:
15973626

Supplemental Content

Support Center